|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 用智能手机高血压指导或追踪应用程序进行家庭血压监测对未控制高血压患者的影响显示文摘移动应用程序(App)可能有助于改善高血压的自我管理。该文旨在探究促进家庭监测和高血压相关行为的人工智能手机指导App与血压追踪App对收缩压水平的影响。设计、设置和参与者:该研究为2组开放性随机临床试验。在2016-2017年招募高血压未控制的参与者,并随访6个月。在2019年4-12月进行数据分析。干预:干预组参与者接受智能手机指导App以促进家庭监测和高血压自我管理相关行为改变,并进行家庭血压监测。 | Persell SD Peprah YA Lipiszko D Lee JY Li JJ Ciolino JD Karmali KN Sato H 袁源(摘译) 练桂丽(审校) | 2020 | 中华高血压杂志2020，28，12： | 11 |
| 2 | Endoscopic management of bariatric complications: A review and update显示文摘With over a third of Americans being considered obese, bariatric procedures have now become the most performed operation be general surgeons in the United States. The most common operations are the Laparoscopic Roux-en-Y Gastric Bypass, the Laparoscopic Sleeve Gastrectomy, and the Laparoscopic Adjustable Gastric Band. With over 340000 bariatric procedures preformed worldwide in 2011, the absolute number of complications related to these operations is also increasing. Complications, although few, can be life threatening. One of the most dreaded acute complication is the anastomotic/staple line leak. If left undiagnosed or untreated they can lead to sepsis, multi organ failure, and death. Smaller or contained leaks can develop into fistulas. Although most patients with an acute anastomotic leak return to the operating room, there has been a trend to manage the stable patient with an endoscopic stent. They offer an advantage by creating a barrier between enteric content and the leak, and will allow the patients to resume enteral feeding much earlier. Fistulas are a complex and chronic complication with high morbidity and mortality. Postoperative bleeding although rare may also be treated locally with endoscopy. Stenosis is a more frequent late complication and is best-managed with endoscopic therapy. Stents may not heal every fistula or stenosis, however they may prevent certain patients the need for additional revisional surgery. | Caolan Walsh Shahzeer Karmali | 2015 | World Journal of Gastrointestinal Endoscopy2015，7，5： | 4 |
| 3 | Laparoscopic resection of pancreatic adenocarcinoma: Dream or reality?显示文摘Laparoscopic pancreatic surgery is in its infancy despite initial procedures reported two decades ago. Both laparoscopic distal pancreatectomy(LDP) and laparoscopic pancreaticoduodenectomy(LPD) can be performed competently; however when minimally invasive surgical(MIS) approaches are implemented the indication is often benign or low-grade malignant pathologies. Nonetheless, LDP and LPD afford improved perioperative outcomes, similar to those observed when MIS is utilized for other purposes. This includes decreased blood loss, shorter length of hospital stay, reduced post-operative pain, and expedited time to functional recovery. What then is its role for resection of pancreatic adenocarcinoma? The biology of this aggressive cancer and the inherent challenge of pancreatic surgery have slowed MIS progress in this field. In general, the overall quality of evidence is low with a lack of randomized control trials, a preponderance of uncontrolled series, short follow-up intervals, and small sample sizes in the studies available. Available evidence compiles heterogeneous pathologic diagnoses and is limited by case-by-case follow-up, which makes extrapolation of results difficult. Nonetheless, shortterm surrogate markers of oncologic success, such as margin status and lymph node harvest, are comparable to open procedures. Unfortunately disease recurrence and long-term survival data are lacking. In this review we explore the evidence available regarding laparoscopic resection of pancreatic adenocarcinoma, a promising approach for future widespread application. | Blaire Anderson Shahzeer Karmali | 2014 | World Journal of Gastroenterology2014，20，39： | 4 |
| 4 | Update on novel endoscopic therapies to treat gastroesophageal reflux disease: A review显示文摘Endoscopic treatments for gastroesophageal reflux disease(GERD) have become increasingly popular in recent years. While surgical intervention with the Laparoscopic Nissen Fundoplication remains the gold standard, two endoscopic interventions, specifically, are gaining traction in clinical use(Esophy X and Stretta). The Esophy X(Endo Gastric Solutions, Inc., Redmond, WA, United States) was developed as a method of restoring the valve at the GE junction through an endoluminal fundoplication(ELF) technique. Long-term data suggests that transoral incisional fundoplication(TIF) with Esophy X may be effective for symptom control and proton pump inhibitor reduction or cessation for up to 2-6 years. There is no evidence that Esophy X is more effective than surgical intervention. TIF may be most effective for patients with HH < 2 cm and Hill Grade I/II valves. Stretta(Mederi Therapeutics, Greenwich, CT, United States) was approved by the Food and Drug Administration in 2000. It delivers radiofrequency energy to the lower esophageal sphincter and gastric cardia. Published reviews of the literature are conflicted in their recommendations of Stretta in the management of GERD. The literature suggests that the Stretta procedure has an acceptable safety profile and may be effective in reducing symptom burden and quality of life scores up to 8 years post-intervention. However, there does not appear to be any sustained improvement in objective outcomes and there is no evidence that Stretta results in improved outcomes as compared to surgical intervention. Treatment modalities for GERD, as a field, suffer from a lack of standardization in primary and secondary outcomes. Although many studies have looked at health related quality of life, the tools used to do so are markedly heterogeneous. Future directions for the endoscopic treatment of GERD include novel techniques like endoscopic submucosal dissection. | Jessica Hopkins Noah J Switzer Shahzeer Karmali | 2015 | World Journal of Gastrointestinal Endoscopy2015，7，11： | 2 |
| 5 | A Review of Laparoscopic Sleeve Gastrectomy for Morbid Obesity显示文摘 | Xinzhe Shi Shahzeer Karmali Arya M. Sharma Daniel W. Birch | 2010 | Obesity Surgery2010，，8： | 2 |
| 6 | Infection by verocytotoxin-producing Escherichia coli显示文摘 | Karmali MA | 1989 | Clin Microbiol Rev1989，2，： | 1 |
| 7 | The po-pulation effects of the global cardiovascular risk model in United States adults:findings from the National Health and Nutrition Surveys,2005-2006显示文摘 | Tattersall MC Karmali KN Gangnon RE | 2011 | J Clin Lipidol2011，5，3： | 1 |
| 8 | Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide,doxorubicin,vincristine,and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lympho显示文摘 | Karmali R Larson M L Wooldridge J E | | 0，，11： | 1 |
| 9 | Minimally invasive splenectomy: an update and review 显示文摘 | Gamme G Birch DW Karmali S | 2013 | Can J Surg2013，，4： | 1 |
| 10 | Sensitive method for detecting low numbers of verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction of verotoxin显示文摘 | KARMALI M A PETRIC M LIM C | 1985 | J Clin Microbiol1985，22，4： | 1 |
| 11 | X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeledbismuth sulfide nanoparticles显示文摘 | KINSELLA J M JIMENEZ R E KARMALI P P | 2011 | Angew Chem Int Ed2011，50，12： | 1 |
| 12 | Sporadic cases of haemolytic -uremic syndrome associated with faecal cytotoxin and cytotoxin--producing Escherichia coil in stools显示文摘 | Karmali MA Steele BT Petric M | 1983 | Lancet1983，1，： | 1 |
| 13 | Cationic liposomes as non-viral carriers of gene medicines : resolved issues,open questions, and future promises显示文摘 | Karmali PP Chaudhuri A | 2007 | Med Res Rev2007，27，5： | 1 |
| 14 | Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis:evidence for a proximal role in Alzheimer's disease显示文摘 | Dodson S E Andersen O M Karmali V | 2008 | J Neurosci2008，28，12： | 1 |
| 15 | Effect of the lipid chain melting transition on the stability of DSPE-PEG (2000) micelles显示文摘 | Kastantin M Ananthanarayanan B Karmali P | | 0，，13： | 1 |
| 16 | Sporadic cases of haemolytie uremic syndrome associated with faecal eytotoxin and cytotoxin-producing Escherichia coli in stools显示文摘 | Karmali M A Steele B T Petrie M | 1983 | Lancet1983，19，1： | 1 |
| 17 | Tissue-penetrating delivery of compounds and nanoparticles into tumors显示文摘 | Sugahara K N Teesalu T Karmali P P | 2009 | Cancer cell2009，16，6： | 1 |
| 18 | Serum creatine kinase levels in overt and subclinical hypothyroidism显示文摘 | Beyer IW Karmali R Demeester-Mirkine N | 1998 | Thyroid1998，8，11： | 1 |
| 19 | Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors显示文摘 | Kazuki N. Sugahara Tambet Teesalu Priya Prakash Karmali Venkata Ramana Kotamraju Lilach Agemy Olivier M. Girard Douglas Hanahan Robert F. Mattrey Erkki Ruoslahti | 2009 | Cancer Cell2009，，6： | 1 |
| 20 | Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs显示文摘 | Sugahara KN Teesalu T Karmali PP | 2010 | Science2010，328，5981： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员